Overview

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Status:
Active, not recruiting

Trial end date:
2026-09-03

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Phase:

Phase 3

Details

Lead Sponsor:

Acerta Pharma BV

Treatments:

Acalabrutinib
Bendamustine Hydrochloride
Idelalisib
Rituximab